News

On the terms of a definitive agreement, both the companies will work together over the next couple of months. Drug delivery platform includes a primary container, a passive

Emmaus is at present conducting a trial, at over 30 sites around the country with over 175 people presently enrolled, which is in Phase III with the FDA

The expanded alliance comprises three components co-development of present and future formulations of migalastat HCl for Fabry disease, commercialisation arrangements for all future Fabry products and increased GSK

The litigation is regarding Mylan Pharmaceuticals’ abbreviated new drug application (ANDA) for Doxepin Hydrochloride Tablets, 3mg and 6mg, indicated for the treatment of insomnia characterized by difficulty with

DSM will provide the process development and cGMP manufacturing services to one of RECEPTA’s lead antibodies at its facilities based in Groningen, The Netherlands. The financial terms of

According to the agreement, BioTime will provide Jade with clinical-grade HyStem hydrogels and certain patented technology for use in the development of new pharmaceutical products for ophthalmologic use.

The randomised, double-blind study will evaluate the efficacy of ticagrelor compared to clopidogrel in reducing the primary endpoint, a composite of CV death, MI or ischaemic stroke, in

AMT is involved in manufacturing mineral ingredients essential to the human diet in the form of chelates as well as custom ingredients for the food, beverage, confectionary and

The enhanced version features notable enhancements, particularly integration with the Amcom Mobile Connect encrypted smartphone communications solution. The new version facilitates Emergency Department Discrepancy Module to identify and